Several types of transgenic mice were used to study the influence of hypertriglyceridemia and cholesteryl ester transfer protein (CETP) expression on high density lipoprotein (HDL) levels, particle sizes, and metabolism. The presence of the CETP transgene in hypertriglyceridemic human apo CIII transgenic mice lowered HDL-cholesterol (HDL-C) 48% and apolipoprotein (apo) A-I 40%, decreased HDL size (particle diameter from 9.8 to 8.8 nm), increased HDL cholesterol ester (CE) fractional catabolic rate (FCR) 65% with a small decrease in HDL CE transport rate (TR) and increased apo A-I FCR 15% and decreased apo A-I TR 29%. The presence of the CETP transgene in hypertriglyceridemic mice with human-like HDL, human apo A-I apo CIII transgenic mice, lowered HDL-C 61% and apo A-I 45%, caused a dramatic diminution of HDL particle size (particle diameters from 10.3 and 9.1 to 7.6 nm), increased HDL CE FCR by 107% without affecting HDL CE TR, and increased apo A-I FCR 35% and decreased apo A-I TR 48%. Moreover, unexpectedly, hypertriglyceridemia alone in the absence of CETP was also found to cause lower HDL-C and apo A-I levels primarily by decreasing TRs. Decreased apo A-I TR was confirmed by an in vivo labeling study and found to be associated with a decrease in intestinal but not hepatic apo A-I mRNA levels. In summary, the introduction of the human apo A-I, apo CIII, and CETP genes into transgenic mice produced a high-triglyceride, low-HDL-C lipoprotein phenotype. Human apo A-I gene overexpression caused a diminution of mouse apo A-I and a change from monodisperse to polydisperse HDL. Human apo CIII gene overexpression caused hypertriglyceridemia with a significant decrease in HDL-C and apo A-I levels primarily due to decreased HDL CE and apo A-I TR but without a profound change in HDL size. In the hypertriglyceridemic mice, human CETP gene expression further reduced HDL-C and apo A-I levels, primarily by increasing HDL CE and apo A-I FCR, while dramatically reducing HDL size. This study provides insights into the genes that may cause the high-triglyceride, low-HDL-C phenotype in humans and the metabolic mechanisms involved. (J.
Introduction
In humans there is a strong association between hypertriglyceridemia and low levels of HDL cholesterol (HDL-C)' and apo A-I, the principal HDL apolipoprotein (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Hypertriglyceridemia is also associated with a greater reduction of HDL-C than apo A-I as well as with decreased HDL particle size (1 1). It has been proposed that these associations are due to increased exchange of core triglycerides in VLDL for core cholesteryl esters in HDL mediated by the cholesteryl ester transfer protein (CETP) driven by elevated plasma concentrations of triglyceride-rich lipoproteins. Triglycerides in HDL are then hydrolyzed by hepatic lipase with diminution ofHDL size, which has been associated with increased fractional catabolic rate (FCR) of apo A-I, perhaps due to increased filtration by the kidney (12) . The evidence for this proposal is based largely on in vitro studies (2) (3) (4) and limited in vivo studies (13) , which are largely correlative. Now, through transgenic technology, it is possible to examine the specific effects of hypertriglyceridemia and CETP on HDL-C and apo A-I levels and metabolism and on HDL size.
Control mice have low triglyceride levels, lack CETP activity in their plasma, and tend to have a single-size distribution of HDL particles. Through the introduction of human lipoprotein transport protein genes, we have been able to make transgenic mice that are a better model for the study ofthe hypertriglyceridemia-low-HDL-C relationship. Through the introduction ofthe human apo CIII gene a hypertriglyceridemic mouse model has been created (14) . These animals accumulate apparently normal VLDL in plasma with the primary metabolic defect in VLDL fractional catabolic rate (15) . Through the introduction ofthe human CETP gene, mice have been created with human-like levels of CETP mass and activity in plasma (16) . These animals showed a modest reduction of HDL-C and very slight reduction of apo A-I levels in their plasma. Finally, by introducing the human apo A-I gene, mice were created with increased levels of HDL-C (17) . In these mice, mouse apo A-I was suppressed and the HDL which contained mostly human apo A-I had several major size distributions of HDL particles comparable to human HDL2b and HDL3a ( 18, 19) . In a recent study we crossed the HuAITg and HuCETPTg mice and showed on the background of human apo A-I that CETP induced a greater reduction of HDL-C and apo A-I levels and HDL particle size (20). In the plasma of these HuAICETPTg mice there was also a stronger HDL-CETP interaction.
In the current study we have crossbred mice with these transgenes to examine the effect of hypertriglyceridemia with or without CETP on the background of mouse or human apo A-I on HDL-C levels, HDL particle sizes, and HDL CE and apo A-I metabolism. We have found that hypertriglyceridemia in the presence of CETP has a profound effect on HDL, but that there is also a previously unsuspected effect in the absence of CETP. These studies help clarify the roles of molecules which may mediate the development ofa common atherogenic lipoprotein phenotype in humans.
Methods
Transgenic mice. Transgenic mice were created as previously described (14) (15) (16) (17) . The fertilized eggs injected with foreign DNA were F1 (C57B1/6J X CBA/J). Transgenic mice were confirmed by tail tip DNA analysis and mated to Fl's ofthe same genetic background. Comparisons in metabolic studies were with nontransgenic litter mates. Four lines of human apo CIII transgenic (HuCIIITg) mice were used (2674, 3641, 3707, 2721). Two ofthese lines were previously described (2674 and 2721) (14) and the other two were made with the same DNA construction. In these lines the apo CIII transgene was expressing primarily in the liver (> 90%) with some intestinal expression (14) . These lines had different mean triglyceride levels which were directly proportional to human apo CIII gene expression (14) . One line of human CETP transgenic (HuCETPTg) mice was used which has been previously described (16) . This line was made with a DNA construction which contains a CETP minigene driven by the mouse metallothionein I (MMTH I) gene promoter. One line of human apo A-I transgenic (HuAITg) mice (179), which was previously described (17), was used. Finally, two lines of transgenic mice (4867, 4868) were used which contained both the human apo A-I and apo CIII genes (21) . In these lines the apo A-I transgene was expressed equally in liver and intestine, with the apo CIII transgene expressed primarily in liver (> 90%) with some intestinal expression. These genes are adjacent to each other on the genome and convergently transcribed. The piece of DNA used extended from 0.3 kb 5' to the apo A-I gene to 1.4 kb 5' to the apo CIII gene. The HuCIIICETPTg mice were generated by crossing HuCIIITg mouse line 3707 with HuCETPTg mice. The HuAICIIICETPTg mice were generated by crossing the HuAICIIITg mouse lines (4867, 4868) with HuCETPTg mice. The HuAICIIITg line was used rather than HuAITg and HuCIIITg lines to minimize the number of crosses required to get animals expressing all three human transgenes. The transgenic lines have been carefully studied for drift of the phenotype with time and none has been observed. In addition, the animals were studied between 10 and 20 wk ofage, during which time in a given mouse there are no significant temporal effects on the lipoprotein phenotype (22) .
Blood samplingprotocol. Animals were placed in metabolic cages in animal rooms with alternating 12-h periods of light (7 a.m. to 7 p.m.) and dark (7 p.m. to 7 a.m.) with ad lib access to food and water. Mice 12-16 wk old (20-30 g in weight) were given a regular mouse laboratory diet (Purina Chow 5001; Ralston Purina Co., St. Louis, MO) and distilled water for 7 d, and then a Chow diet and water, supplemented with 25 mM ZnSO4 for 7 d to raise the level of plasma CETP. At the end of each 7-d period, the mice were fasted overnight and blood was collected the following morning from the retroorbital plexus under methoxyflurane anesthesia.
Plasma lipid and lipoprotein analysis. Triglyceride and total cholesterol were determined enzymatically using the Boehringer Mannheim (Indianapolis, IN) reagents (nos. 126012 and 236691, respectively).
HDL and other lipoprotein fractions were separated by ultracentrifugation in an Airfuge (Beckman, Instruments, Inc., Fullerton, CA) as previously described (17) . In the HDL fraction, free cholesterol and total cholesterol (after saponification) were measured by gas chromatography with coprostanol as an internal standard. The cholesterol ester (CE) was taken as the difference between the two. Nondenaturing gradient gel electrophoresis. HDL particle size distribution was evaluated as previously described (23, 24) . Plasma specimens from control, HuCIIITg, HuCIIICETPTg, HuAITg, HuAICIIITg, and HuAICIIICETPTg mice were subjected to gradient gel electrophoresis. In a 175-Ml airfuge tube, 40 Ml of plasma was adjusted to d 1.21 g/ml with 1.35 g/ml KBr and 1 mM EDTA. This mixture/solution was then ultracentrifuged at 100,000 g for 5 h (Airfuge). 30 Al was then aspirated from the top ofthe tube, electrophoresed for 20 min at 70 V and then for 18-24 h at 125 V on nondenaturing 4-30% polyacrylamide gradient gels (PAA 4/30, Pharmacia LKB, Piscataway, NJ). Gels were simultaneously stained and fixed in 0.05% Coomassie Blue R-250 (Bio-Rad Laboratories, Richmond, CA), 9% acetic acid, and 20% methanol, then destained with two changes of 9% acetic acid 20% methanol followed by 9% acetic acid. Stained gels were scanned using a digital scanning densitometer (model 620, Bio Rad Laboratories) equipped with a 600-nm interference filter, and the data were entered into a personal computer. Scans were analyzed by Gaussian modeling as described previously (24) . Stokes' radius ofHDL particles was estimated by comparing migration distances with those of thyroglobulin (8.50 nm), apoferritin (6.10 (25) . Lipoproteins were eluted at 0.3 ml/min with 1 mM EDTA, 154 mM NaCl. After the initial 12 ml had eluted, 50 fractions (0.5 ml) were collected. 60 ml of buffer was passed through the columns between sample loading. Cholesterol and triglyceride concentrations in the fractions were measured enzymatically using Boehringer Mannheim kits. Recoveries of total cholesterol and triglycerides were 90% and 87%, respectively.
Quantitation of plasma apolipoproteins. Human apo CIII was quantified by rocket immunoelectrophoresis using an anti-human apo CIII antibody that had < 0.01% cross-reactivity with mouse apo CIII (14) . Mouse apo A-I was quantified by rocket immunoelectrophoresis using a polyclonal anti-mouse apo A-I antibody prepared in cynomolgus monkeys generously provided by Dr. George Melchior of the Upjohn Company (18) . This antibody had < 0.01% cross-reactivity with human apo A-I. Human apo A-I was quantified by the turbidity method using a polyclonal goat anti-human apo A-I antibody that had < 0.01% cross-reactivity with mouse apo A-I (17) .
Plasma CETP concentration. Plasma CETP concentration was measured by solid-phase radioimmunoassay as described previously (26) .
Preparation of HDL labeled in the apo A-I and cholesteryl ester moieties. Human and mouse apo A-I were purified and radiolabeled with 1251 by the Bilheimer modification of the McFarlane method, as previously described (27, 28 (18, 20, 29) .
In vivo turnover studies. Methoxyflurane anesthetized mice were injected intravenously (femoral vein) with either control or HuAITg mouse HDL doubly labeled with 2-4 gg of '25I-mouse or human apo A-I, respectively, and 100,000-200,000 dpm of [3H] cholesteryl oleoyl ether, as previously described (18, 20 quantified by a solution hybridization RNase protection assay with a riboprobe to detect mouse apo A-I mRNA, as previously dg!ribed (31, 32) . With the animals allowed free access to food and w ijliver and small intestine were taken from control and HuCIIITg r.NA was isolated by the method of Chomczynski and Sacchi (33) . kground counts per minute for the probe was routinely < 0.4% of total counts using the filter counting assay. Statistical analysis. Results are expressed as mean±SE ofthe mean.
The Student t test was used to compare differences between groups.
Statistical significance was defined as P < 0.05.
Results
Several types of transgenic mice were used to study the was injected intravenously into HuCIIITg, HuCIIICETPTg, HuAICIIITg, and HuAICIIICETPTg mice and the plasma disappearance of radioactivity followed, as shown in Fig. 3 . The Matthews method was used to calculate HDL CE FCR and apo A-I FCR and these multiplied by the pool size (as reflected by the plasma concentration ofHDL CE and total apo A-I, respectively) estimated the transport rates (TR). These results are summarized in Table II . Compared with HuCIIITg mice, the HuCIIICETPTg mice had a 65% higher HDL CE FCR, which accounted for most ofthe decrease in HDL-C levels. Similarly, compared with HuAICIIITg mice, the HuAICIIICETPTg mice had a 107% increase in HDL CE FCR which also accounted for most of the HDL-C decrease. CETP expression significantly decreased HDL CE TR in the HuCIIICETPTg animals, but in the HuAICIIICETPTg animals the effect was not significant. With regard to apo A-I, on the mouse apo A-I background CETP significantly increased apo A-I FCR 15% and decreased apo A-I TR 29%. On the human apo A-I background, CETP significantly increased apo A-I FCR 35% and decreased apo A-I TR 48%. Thus, in both cases the decrease in apo A-I levels was due to changes in both FCR and TR, with the latter perhaps contributing more than the former.
These experiments with transgenic mice clearly show that CETP is a major mediator of the inverse relationship between triglyceride and HDL-C level. However, in performing these experiments it was unexpectedly noted that this relationship also existed in the absence of CETP. The triglyceride-HDL-C relationship is shown in Fig. 4 for the HuCIIITg line 3707 in the presence and absence of CETP. The regression line is steeper and shifted to the left in the presence of CETP (at the same level of triglycerides lower HDL-C levels). The inverse correlation of triglycerides and HDL-C levels in the absence of CETP was seen within several different HuCIIITg lines and also between lines with different amounts of apo CIII expression and differing triglyceride levels. In four different HuCIIITg lines as the triglyceride levels increased, HDL-C levels decreased (Table III) From both the in vivo turnover and in vivo labeling studies, it seems that HuCIIITg mice have lower apo A-I synthetic rates compared to controls. To examine whether this reduction is transcriptional, mouse apo A-I mRNA levels were measured in total RNA isolated from liver and small intestine of both control and HuCIIITg mice (line 2721) by a solution hybridization/RNase protection assay using mouse apo A-I mRNA specific riboprobes. As shown in Table VI , intestinal mouse apo A-I mRNA levels were reduced significantly in HuCIIITg compared to control mice, while the hepatic mouse apo A-I mRNA levels were unchanged. This suggests that the reduction of mouse apo A-I levels in HuCIIITg mice (line 2721) might be mediated in part by modulation of intestinal apo A-I synthesis. There was no significant difference in the rate of appearance of [35S]methionine into albumin between the two groups (see Fig.  5 , legend). 
Discussion
In humans there is a well-known association of high triglycerides with low HDL-C levels (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . This relationship is thought, but not proven, to arise from core lipid exchange be- HDL in the plasma of hypertriglyceridemic patients (34) , and that CETP infusion into hypertriglyceridemic sucrose-fed rats lowers HDL-C levels and particle sizes (13) . The current study in transgenic mice provides direct proof of the important role of CETP in the high-triglyceride-low-HDL-C level relationship. Hypertriglyceridemia was produced in mice by overexpression of the human apo CIII gene. The major metabolic mechanism in these mice appears to be reduced VLDL FCR (15) . At this time we cannot be certain ifthe effects of hypertriglyceridemia that were observed are mechanism-specific, in that this is the only available model of mouse hypertriglyceridemia in the absence of other major metabolic disturbances (i.e., diabetes). The coexpression ofhypertriglyceridemia and CETP showed an additive effect on HDL-C levels ( Fig. 4 and Table I ) and a strong interactive effect to decrease apo A-I levels (Table I) . However, in the case of HDL particle size, hypertriglyceridemia or CETP expression alone had minimal effect on HDL particle size, but when coexpressed revealed a profound interaction (Fig. 1) . This may reflect a need for triglyceride enrichment of HDL for hepatic lipase to decrease HDL size (3). In addition, in the absence of CETP we did observe an inverse relationship oftriglycerides and HDL-C levels. This was most apparent in animals with marked hypertriglyceridemia (Table III) and appears to involve decreased HDL CE and apo A-I TR. In homozygous CETP-deficient patients, an inverse relationship of triglycerides and HDL-C levels was not observed (35) . However, these individuals had triglyceride levels < 400 mg/dl, which may not have been high enough to observe this relationship. Finally, although this was not addressed in the current study, recently another group created CETP transgenic mice and found that decreased HDL-C was accompanied by increased VLDL-C and LDL-C levels, as expected from studies in humans (35) (36) (37) .
In hypertriglyceridemic humans low HDL-C levels are associated with a reduction in HDL particle size (2, 3). The basis for this association was explored in the transgenic mouse model. In control mice HDL consists primarily of a single particle size distribution, diameter 10 nm; in hypertriglyceridemic HuCIIITg mice the particle diameter is unchanged. In a previous study we noted that the introduction of CETP into normotriglyceridemic mice reduced HDL particle diameter to 9.7 nm (16, 20) . However, in the current study the combined effect ofhypertriglyceridemia and CETP in the HuCIIICETPTg mice reduced HDL particle diameter to 8.8 nm, demonstrating that the effect of hypertriglyceridemia on HDL particle size in the mouse is mediated virtually completely through CETP with a large synergistic effect.
Although interesting, these studies in the mouse ofthe association ofhypertriglyceridemia with small HDL suffer from the fact that mouse HDL particle size distribution (monodisperse) is unlike humans. Normotriglyceridemic humans typically have two main HDL particle size distributions: HDL2b, diameter 10.8 nm, and HDLu, diameter 9.0 nm (24) . In hypertriglyceridemic humans the larger HDL2b tend to diminish with the appearance of smaller HDL species, such as HDL3b, diameter 8.4 nm, and HDL3c, diameter 7.8 nm (2) . The biochemical basis for the difference in HDL particle size distribution between mouse and human was revealed by previous transgenic mouse experiments (18) . HuAITg mice, in which human apo A-I virtually replaces mouse apo A-I, show HDL particle size distribution similar to humans, implicating the physical differences between human and mouse apo A-I as the underlying basis for the species differences. Therefore, it was of interest to study the high-triglyceride-small-HDL association in the mouse on the background of human apo A-I. In HuAITg mice HDL2b, diameter 10.3 nm, and HDL3a, diameter 9.1 nm, were observed, as before (18) . In hypertriglyceridemic HuAICIIITg mice there was a diminution ofthe HDL2b and the appearance of HDL3b, diameter 8.3 nm, and HDL3, diameter 7.6 nm. Thus, on the background of human apo A-I, hypertriglyceridemia alone shifted the HDL to smaller particle size distribution. Finally, the most striking effect of all was achieved with the combined effect of hypertriglyceridemia and CETP in the HuAICIIICETPTg mice. All large HDL disappeared, with only HDL3c, particle size 7.6 nm, remaining. This is quite comparable to HDL size seen in humans with triglycerides > 500 mg/dl (2) and proves that this phenotype is due to a triglyceride-CETP interaction.
The high-triglyceride-low-HDL-C level lipoprotein pattern is associated with atherosclerosis susceptibility (5, 38) . One proposed mechanism is that there is diminished reverse cholesterol transport ofHDL CE from the artery wall to the liver (39) . Although our measurement of HDL CE TR cannot be assumed to be totally due to unidirectional flux of cholesterol from peripheral tissues to the liver, it was ofinterest to examine apo A-I overproduction by the human apo A-I transgene to raise HDL-C levels (17, 18) . It would be of interest to study atherosclerosis susceptibility in the HuCIIICETPTg and HuAICIIICETPTg animals on various diets to see whether the high-triglyceride-low-HDL-C level phenotype is actually atherogenic. The current studies also allow an examination of the effect ofthe hypertriglyceridemia phenotype on HDL particle metabolism through examination of apo A-I turnover. In the current study and previous ones (18, 20) , control mouse apo A-I FCR was 0.1 1, 0.12, and 0.10 pools per hour and HuAITg mouse apo A-I FCR was 0.13 and 0.12 pools per hour. On the background ofmouse and human apo A-I, adding either apo CIII or CETP, as seen in studies of HuCETPTg, HuAICETPTg, HuCIIITg, and HuAICIIITg mice, produced about a 10% increase in apo A-I FCR. However, the combined effect ofhypertriglyceridemia and CETP further elevated the apo A-I FCR to 0.14 in the HuCIIICETPTg mice and 0.17 in the HuAICIIICETPTg mice. In HDL apolipoprotein turnover studies in humans, we previously showed that apo A-I FCR was best predicted by HDL size (41, 42) . Inasmuch as in rodents a major site of apo A-I catabolism is the proximal tubules ofthe kidney (12) , a possible mechanism may be that small HDL have enhanced kidney filtration and catabolism of apo A-I. Thus, the diminution ofHDL size in the HuCIIICETPTg and HuAICIIICETPTg mice may account for this increase in apo A-I FCR. The lowering of plasma apo A-I levels by hypertriglyceridemia and CETP was only partially accounted for by an increase in apo A-I FCR, and there was a significant component of decreased apo A-I TR. The mechanism of this unexpected finding was further explored in the HuCIIITg mouse line 2721 with severe hypertriglyceridemia. In these animals both in vivo metabolic and labeling studies indicated decreased apo A-I synthesis accompanied by a specific decrease in intestinal but not hepatic apo A-I mRNA levels. Thus, in hypertriglyceridemia there might be a decrease in intestinal apo A-I production. In hypertriglyceridemic humans there is an expanded bile acid pool size (43, 44) and this may regulate intestinal apo A-I synthesis, although other mechanisms are certainly possible.
Finally, what are the implications of the transgenic mouse model for understanding the low HDL-C risk factor associated with atherosclerosis susceptibility in humans? In the transgenic mice we showed that high triglycerides act synergistically with CETP to cause low HDL-C levels, reduce HDL particle sizes, increase HDL CE FCR and apo A-I FCR, and decrease HDL CE and apo A-I TR. Thus, the transgenic mouse model proves that high triglycerides in the presence of CETP in vivo can cause the low HDL-C, diminished HDL particle size, and increased apo A-I FCR phenotype associated with heart disease susceptibility. In a previously published human metabolic study we found that, compared with controls, hypertriglyceridemic low HDL-C patients had increased apo A-I FCR but normal apo A-I TR, and the increased apo A-I FCR correlated strongly with decreased HDL particle size (41, 42) . In the human study the decrease in apo A-I levels associated with hypertriglyceridemia was only 12%, whereas in the mice it was 50%. The much greater reduction in mice may be due to the combined effect of hypertriglyceridemia on increasing apo A-I FCR and decreasing apo A-I TR.
Thus, the transgenic mouse model described herein reproduces most aspects of the human condition. However, it is probable that other genes also play a role in the complex processes that lead to the low HDL-C level phenotype. Evidence for this comes from two types of studies in humans. First, although most individuals with low HDL-C levels have high triglycerides, some do not. We have previously shown that these people, too, have increased apo A-I FCR, normal apo A-I TR, and diminished HDL particle size (41) . In addition, in patients with high triglycerides and low HDL-C, normalization of triglycerides by diet and drug therapy does not elevate HDL-C levels in some individuals (45) (46) (47) . Thus, the low HDL-C, increased apo A-I FCR condition can be caused by mechanisms independent of a primary increase in triglyceride levels, such as primary alterations in lipoprotein and/or hepatic lipase, as suggested by Goldberg et al. (7), Kunsi et al. (48) , Kekki (49) , and Applebaum-Bowden et al. (50) .
